Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

{{::item.ticker}} • {{::item.company_name}} No Results

Get All Access for FREE

Market News & Research,
Fundamental Data,
Live Transcripts & Audio,
AlphaGraphics,

and a whole lot more…

News & Research
Portfolio
Discover
Groups
$HOLX {{ '2017-11-08T22:16:36+0000' | timeago}} • Infographic

$HOLX Hologic, Inc. Earnings AlphaGraphic: Q4 2017 Highlights

$HOLX {{ '2018-01-16T13:05:50+0000' | timeago}} • Announcement

$HOLX said its CE-marked Aptima HIV-1 Quant Dx assay has been awarded World Health Organization (WHO) prequalification for in vitro diagnostic. The Aptima HIV-1 Quant Dx assay is the first HIV-1 viral load assay with a dual claim for both diagnosis and treatment monitoring.

$HOLX {{ '2018-01-11T21:23:15+0000' | timeago}} • Announcement

Medical technology company $HOLX has elected Namal Nawana to its board of directors, effective immediately. Nawana was formerly the CEO of Alere, Inc. Prior to that, he served Johnson & Johnson in various leadership roles, including Worldwide President of DePuy Synthes Spine.

$HOLX {{ '2018-01-08T13:10:32+0000' | timeago}} • Announcement

Medical technology company $HOLX said it is currently looking for net revenues of about $791MM for the first quarter of 2018, higher than $775MM-$790MM the company had estimated earlier. The latest guidance represents an 8% YoY growth, reflecting the effect of divestiture of Hologic’s blood screening business and acquisition of Cynosure.

$HOLX {{ '2018-01-03T13:10:03+0000' | timeago}} • Announcement

$HOLX said the MyoSure MANUAL device, which was designed to simplify tissue removal procedures regardless of setting, has received CE mark in Europe. The MyoSure MANUAL device joins the MyoSure suite of gynecologic surgical products that offer simple and effective solutions to resect and remove tissue.

$HOLX {{ '2017-11-27T12:28:43+0000' | timeago}} • Announcement

Medical technology company $HOLX has signed a development and distribution agreement with Clarius Mobile Health, a manufacturer of ultrasound scanners, for supply of handheld wireless scanners. The devices will be used for early detection of breast cancer. The company did not disclose the financial terms of the agreement.

$HOLX {{ '2017-11-09T15:40:48+0000' | timeago}} • Announcement

For FY18, $HOLX expects revenue to be $3.20-3.28Bil, GAAP EPS to be $1.22-1.27 and non-GAAP EPS is estimated to be $2.10-2.15. For 1Q18, revenue is estimated to be $775-790MM, GAAP EPS to be $0.25-0.27 and non-GAAP EPS is targeted $0.48-0.50.

$HOLX {{ '2017-11-09T15:34:46+0000' | timeago}} • Announcement

$HOLX's profit dropped 10% in its final quarter of FY17 despite a 11% increase in the revenue. Net income was $83MM or $0.29 per share on revenues of $803MM. On a non-GAAP basis, Hologic earned $0.50 per share.

$HOLX {{ '2017-11-08T22:16:36+0000' | timeago}} • Infographic

$HOLX Hologic, Inc. Earnings AlphaGraphic: Q4 2017 Highlights

$HOLX {{ '2017-10-17T12:00:00+0000' | timeago}} • Announcement

Medical technology company $HOLX said the European Medical Device Directive has granted an additional certification for its body contouring laser treatment SculpSure. The certification allows the company to use the device in the European Union and its member states.

$HOLX {{ '2017-10-05T20:22:56+0000' | timeago}} • Announcement

$HOLX received 510(k) clearance from FDA for its Panther Fusion Flu A/B/RSV assay running on the new Panther Fusion system. The company said new Panther Fusion module expands system's molecular testing capabilities, increases efficiency and flexibility for the laboratory.

$HOLX {{ '2017-10-04T12:39:26+0000' | timeago}} • Announcement

Medical technology company $HOLX has launched a private offering of $350MM aggregate principal amount of senior notes due 2025.  Hologic plans to use the proceeds from the offering, along with cash, to retire its remaining convertible notes when they become callable in December 2017 and March 2018.

$HOLX {{ '2017-10-04T12:25:12+0000' | timeago}} • Announcement

Medical technology company $HOLX has launched a private offering of $350MM aggregate principal amount of senior notes due 2025.  Hologic plans to use the proceeds from the offering, along with cash, to retire its remaining convertible notes when they become callable in December 2017 and March 2018.

$HOLX {{ '2017-09-27T13:00:18+0000' | timeago}} • Announcement

$HOLX received FDA 510(k) clearance to market SculpSure for non-invasive body contouring (lipolysis) of the submental area (under the chin). SculpSure is also cleared to treat the abdomen, love handles (flanks), back, and inner and outer thighs.

$HOLX {{ '2017-06-20T15:15:28+0000' | timeago}} • Announcement

$HOLX has obtained FDA clearance to market the Aptima Herpes Simplex Virus (HSV) 1 & 2 molecular assay on the fully automated Panther system. The test will be commercially available in the 50 United States, US territories and Puerto Rico.

$HOLX {{ '2017-06-15T13:06:41+0000' | timeago}} • Announcement

$HOLX said that the FDA has granted an expanded clearance for Cynosure's body contouring product, SculpSure, to treat the back and inner and outer thighs. The SculpSure treatment is already FDA-cleared for treatment of the abdomen and love handles.

$HOLX {{ '2017-05-16T20:13:23+0000' | timeago}} • Announcement

$HOLX announced that Charles J. Dockendorff has been elected to the company's Board of Directors, effective immediately.  Mr. Dockendorff also was appointed to the Audit and Finance Committee.

$HOLX {{ '2017-05-10T21:41:36+0000' | timeago}} • Webcast

$HOLX feels positive about its global molecular business which is becoming its largest product franchise and is accretive to its growth rate. The company is optimistic about the direction of this business going forward.

$HOLX {{ '2017-05-10T21:18:47+0000' | timeago}} • Webcast

$HOLX said there was no pricing impact to gross margins. The company is pleased with its pricing across all divisions. The GM impact was due to the blood screening divestiture. The over-performance of the blood screening was at a fairly low margin which impacted $HOLX negatively. FX and product mix also impacted GM but this was not significant.

$HOLX {{ '2017-05-10T21:13:17+0000' | timeago}} • Webcast

$HOLX said the international Breast Health business grew at about mid-single digit rate while the overall international business grew at double-digit rate. In the US, there is a bit of uncertainty due to the state of healthcare reform but this has not affected big hospitals. $HOLX is seeing slower growth in the US which it believes will improve.

$HOLX {{ '2017-05-10T20:34:08+0000' | timeago}} • Announcement

In 2Q17, $HOLX posted US sales of $570.1MM, up 4.1%. International sales of $145.3MM decreased 0.1%, but increased 2.8% in constant currency, led by strong growth in molecular diagnostics, GYN Surgical and Breast Health. GYN Surgical revenue of $101.1MM increased 11.2%. Breast Health revenue totaled $280.5MM, up 1.7% versus 2Q16.

Recent Transcripts
ISRG | Earnings
July 19th 2018, 8:30pm
ONVO | Earnings
May 31st 2018, 9:00pm
MDT | Earnings
May 24th 2018, 12:00pm
PTN | Earnings
May 15th 2018, 3:00pm
AlphaGraphics you may like
Related Feed
Recent Transcripts
ISRG | Earnings
July 19th 2018, 8:30pm
ONVO | Earnings
May 31st 2018, 9:00pm
MDT | Earnings
May 24th 2018, 12:00pm
PTN | Earnings
May 15th 2018, 3:00pm
AlphaGraphics you may like